New fluorescent chemical tools reveal for the first time how potent dual-agonist drugs for diabetes and obesity precisely target cells in the pancreas and brain to achieve their superior effects.
Most Recent Articles
Thirty-Eight-Year Analysis of Pediatric Heart Transplantation in the Scandiatransplant Region
A 38-year study of Nordic pediatric heart transplantation reveals a significant decline in waiting-list mortality, despite longer wait times. At the same time, long-term survival after transplant remains strong but has not...
A Data-Driven Reclassification of Multiple Sclerosis Defines a Continuous Disease Spectrum
A groundbreaking AI model redefines multiple sclerosis not as distinct subtypes but as a single, continuous disease process driven by inflammation, paving the way for individualized patient care.
Efficacy and Safety of Canagliflozin in Children and Adolescents With Type 2 Diabetes
A phase 3 clinical trial finds the SGLT2 inhibitor canagliflozin significantly improves glycemic control in children and adolescents with type 2 diabetes, offering a new potential treatment option.
Hemodynamic Impact of “Clear” E-Cigarettes with Synthetic Cooling Agents
New research shows that "clear" e-cigarettes contain synthetic coolants and cause greater acute spikes in blood pressure and heart rate than other flavored vapes.
